Literature DB >> 22057284

Lewis score correlates more closely with fecal calprotectin than Capsule Endoscopy Crohn's Disease Activity Index.

Anastasios Koulaouzidis1, Sarah Douglas, John N Plevris.   

Abstract

BACKGROUND: Small-bowel capsule endoscopy (SBCE) is an invaluable imaging method for the small bowel. The Lewis score (LS) and the Capsule Endoscopy Crohn's Disease Activity Index (CECDAI) have been developed to standardize the reporting of small-bowel inflammation. Fecal calprotectin (FC) represents a highly reliable biomarker of intestinal inflammation. AIM: To assess the performance of the two SBCE inflammation scoring systems by correlating them with FC. Furthermore, to define threshold levels for CECDAI.
METHODS: Retrospective study; patients who underwent SBCE and had FC measurement shortly before or after SBCE. LS and CECDAI were calculated by a single reviewer and correlated [Spearman's (r ( s ))] with the FC results. Linear regression analysis was used to identify threshold levels for CECDAI.
RESULTS: Forty-nine patients; three subgroups A, B and C (based on FC levels <100, 100-200, and ≥200 μg/g, respectively). LS appears to correlate with FC (r ( s ) = 0.448, p = 0.0014), unlike CECDAI, which does not demonstrate significant correlation (r ( s ) = 0.245, p = 0.089). Strongly positive correlation between FC and LS was observed in subgroup A (r ( s ) = 0.68, p = 0.0047), while in subgroups B and C, neither LS nor CECDAI showed correlation with FC. Significant correlation between LS and CECDAI was demonstrated (r ( s ) = 0. 6324, p < 0.0001). Linear regression analysis demonstrates that LS thresholds of 135 and 790 correspond with CECDAI levels of 3.8 and 5.8, respectively.
CONCLUSIONS: LS performs better than CECDAI in describing small-bowel inflammation, especially at FC levels of <100 μg/g. Furthermore, CECDAI levels of 3.8 and 5.8 seem to correspond to LS thresholds of 135 and 790, respectively.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22057284     DOI: 10.1007/s10620-011-1956-8

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  25 in total

1.  Faecal lactoferrin, capsule endoscopy and Crohn's disease. Is there a three way relationship? A pilot study.

Authors:  Reena Sidhu; David S Sanders; Perm Wilson; Laura Foye; Stephen Morley; Mark E McAlindon
Journal:  J Gastrointestin Liver Dis       Date:  2010-09       Impact factor: 2.008

2.  Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study.

Authors:  A G Røseth; M K Fagerhol; E Aadland; H Schjønsby
Journal:  Scand J Gastroenterol       Date:  1992-09       Impact factor: 2.423

3.  Faecal calprotectin for the diagnosis of inflammatory bowel disease.

Authors:  Robert Logan
Journal:  BMJ       Date:  2010-07-15

4.  Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.

Authors:  Jost Langhorst; Sigrid Elsenbruch; Julia Koelzer; Andreas Rueffer; Andreas Michalsen; Gustav J Dobos
Journal:  Am J Gastroenterol       Date:  2007-10-04       Impact factor: 10.864

5.  A simple method for assessing intestinal inflammation in Crohn's disease.

Authors:  J Tibble; K Teahon; B Thjodleifsson; A Roseth; G Sigthorsson; S Bridger; R Foster; R Sherwood; M Fagerhol; I Bjarnason
Journal:  Gut       Date:  2000-10       Impact factor: 23.059

6.  A meta-analysis of the yield of capsule endoscopy compared to other diagnostic modalities in patients with non-stricturing small bowel Crohn's disease.

Authors:  Stuart L Triester; Jonathan A Leighton; Grigoris I Leontiadis; Suryakanth R Gurudu; David E Fleischer; Amy K Hara; Russell I Heigh; Arthur D Shiff; Virender K Sharma
Journal:  Am J Gastroenterol       Date:  2006-05       Impact factor: 10.864

7.  Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease.

Authors:  A G Røseth; P N Schmidt; M K Fagerhol
Journal:  Scand J Gastroenterol       Date:  1999-01       Impact factor: 2.423

8.  The potential value of faecal lactoferrin as a screening test in hospitalized patients with diarrhoea.

Authors:  D R van Langenberg; R B Gearry; H-L Wong; M Ward; P R Gibson
Journal:  Intern Med J       Date:  2010-12       Impact factor: 2.048

Review 9.  Expanding role of capsule endoscopy in inflammatory bowel disease.

Authors:  Blair-S Lewis
Journal:  World J Gastroenterol       Date:  2008-07-14       Impact factor: 5.742

Review 10.  Role of small-bowel endoscopy in the management of patients with inflammatory bowel disease: an international OMED-ECCO consensus.

Authors:  A Bourreille; A Ignjatovic; L Aabakken; E V Loftus; R Eliakim; M Pennazio; Y Bouhnik; E Seidman; M Keuchel; J G Albert; S Ardizzone; S Bar-Meir; R Bisschops; E J Despott; P F Fortun; R Heuschkel; J Kammermeier; J A Leighton; G J Mantzaris; D Moussata; S Lo; V Paulsen; J Panés; G Radford-Smith; W Reinisch; E Rondonotti; D S Sanders; J M Swoger; H Yamamoto; S Travis; J-F Colombel; A Van Gossum
Journal:  Endoscopy       Date:  2009-07-08       Impact factor: 10.093

View more
  36 in total

1.  Correlation of two capsule endoscopy scoring systems with fecal calprotectin: does it really matter?

Authors:  Suryakanth R Gurudu; Jonathan A Leighton
Journal:  Dig Dis Sci       Date:  2012-04       Impact factor: 3.199

Review 2.  New vision in video capsule endoscopy: current status and future directions.

Authors:  Laurel R Fisher; William L Hasler
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-05-08       Impact factor: 46.802

Review 3.  Small-bowel capsule endoscopy: a ten-point contemporary review.

Authors:  Anastasios Koulaouzidis; Emanuele Rondonotti; Alexandros Karargyris
Journal:  World J Gastroenterol       Date:  2013-06-28       Impact factor: 5.742

4.  Mucosal healing effect of mesalazine granules in naproxen-induced small bowel enteropathy.

Authors:  István Rácz; Milán Szalai; Valéria Kovács; Henriett Regőczi; Gyöngyi Kiss; Zoltán Horváth
Journal:  World J Gastroenterol       Date:  2013-02-14       Impact factor: 5.742

5.  Prospective postsurgical capsule endoscopy in patients with Crohn's disease.

Authors:  Tomoaki Kono; Nobuyuki Hida; Koji Nogami; Masaki Iimuro; Yoshio Ohda; Yoko Yokoyama; Koji Kamikozuru; Katsuyuki Tozawa; Mikio Kawai; Tomohiro Ogawa; Kazutoshi Hori; Hiroki Ikeuchi; Hiroto Miwa; Shiro Nakamura; Takayuki Matsumoto
Journal:  World J Gastrointest Endosc       Date:  2014-03-16

Review 6.  Video capsule endoscopy in inflammatory bowel disease.

Authors:  Paul D Collins
Journal:  World J Gastrointest Endosc       Date:  2016-07-25

Review 7.  Capsule endoscopy: Present status and future expectation.

Authors:  Mahesh K Goenka; Shounak Majumder; Usha Goenka
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

Review 8.  Current role of capsule endoscopy in Crohn's disease.

Authors:  Marisol Luján-Sanchis; Laura Sanchis-Artero; Laura Larrey-Ruiz; Laura Peño-Muñoz; Paola Núñez-Martínez; Génesis Castillo-López; Lara González-González; Carlos Boix Clemente; Cecilia Albert Antequera; Ana Durá-Ayet; Javier Sempere-Garcia-Argüelles
Journal:  World J Gastrointest Endosc       Date:  2016-09-16

9.  Comparison of Lewis Score and Capsule Endoscopy Crohn's Disease Activity Index in Patients with Crohn's Disease.

Authors:  Teppei Omori; Harutaka Kambayashi; Shun Murasugi; Ayumi Ito; Maria Yonezawa; Shinichi Nakamura; Katsutoshi Tokushige
Journal:  Dig Dis Sci       Date:  2019-09-20       Impact factor: 3.199

10.  Serum calprotectin levels correlate with biochemical and histological markers of disease activity in TNBS colitis.

Authors:  Didia Bismara Cury; Sender Jankiel Mizsputen; Clara Versolato; Luciana Odashiro Miiji; Edson Pereira; Maria Aparecida Delboni; Nestor Schor; Alan C Moss
Journal:  Cell Immunol       Date:  2013-04-23       Impact factor: 4.868

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.